Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A2YNT30
Fri, 09.05.2025
Alzchem Group AG
Alzchem Group AG: Annual General Meeting approves 50% dividend increase to EUR 1.80 and re-election of Supervisory Board members
Trostberg, May 9, 2025 – The shareholders of Alzchem Group AG, a globally active specialty chemicals company, approved all items on the agenda put to a vote at the Annual General Meeting with a large majority. Among oth [ … ]
Wed, 30.04.2025
Alzchem Group AG
Alzchem Group AG continues earnings growth in the first quarter of 2025; projects to expand nitroguanidine capacity launched
Group EBITDA grows by 10% to EUR 27.4 million with 4% lower revenue
Specialty chemicals are growth drivers
Forecast for further sales and EBITDA growth in 2025 confirmed
Trostberg, April 30, 2025 – Alzchem Group AG, a glo [ … ]
Fri, 21.03.2025
Alzchem Group AG
EQS-Media / 21.03.2025 / 13:52 CET/CEST
Alzchem Group AG: Successful Creatine Conference 2025 inspires international experts
The Alzchem Group brought together leading experts in creatine research in Munich from March 12 to 15, 2025. The Creatine Conference became a meeting place for scientists, health and nutrition experts, trade press and [ … ]
Mon, 17.03.2025
Alzchem Group AG
Alzchem Group AG
Disclosure
according to Article 5 of the EU Regulation 596/2014 and
Article 2 Section (1) of the Delegated EU Regulation 2016/1052
Trostberg, March 17, 2025
Temporary Interruption of Share Repurchase Programme
Due to its Annual Shareholders Meeting to be held on May 8, 2025, Alzchem Group AG temporarily inter [ … ]
Mon, 03.03.2025
Alzchem Group AG
EQS-Media / 03.03.2025 / 17:12 CET/CEST
Alzchem Group invites you to the Creatine Conference 2025: Munich is becoming a hotspot for creatine research
The Alzchem Group is once again bringing together the brightest minds in creatine research in 2025 – in the heart of Munich. From March 12 to 15, 2025, the Meliá Hotel will be transformed into a [ … ]
Fri, 28.02.2025
Alzchem Group AG
Alzchem Group AG achieves record EBITDA of EUR 105.3 million (+29.4%) in fiscal year 2024
Free cash flow climbs significantly by 42.3% to EUR 74.2 million
Dividend to be increased by 50% from EUR 1.20 to EUR 1.80
Further sales and EBITDA growth forecast for 2025
Trostberg, February 28, 2025 – Alzchem Group AG, a globally active specialty chemic [ … ]
Mon, 17.02.2025
Alzchem Group AG
Disclosure according to Article 5 of the EU Regulation 596/2014 and
Article 2 Section (1) of the Delegated EU Regulation 2016/1052
Trostberg, February 17th, 2025
9th Interim Report
In the period from February 10th up to and including February 14th, 2025, a total of 8,730 shares of Alzchem Group AG were acquired as part of the sha [ … ]
Mon, 10.02.2025
Alzchem Group AG
Disclosure according to Article 5 of the EU Regulation 596/2014 and
Article 2 Section (1) of the Delegated EU Regulation 2016/1052
Trostberg, February 10, 2025
8.Interim Report
In the period from February 3 up to and including February 7, 2025, a total of 7.217 shares of Alzchem Group AG were acquired as part of the share buyback [ … ]
Mon, 03.02.2025
Alzchem Group AG
Disclosure according to Article 5 of the EU Regulation 596/2014 and
Article 2 Section (1) of the Delegated EU Regulation 2016/1052
Trostberg, February 3rd, 2025
7th Interim Report
In the period from January 27th up to and including January 31st, 2025, a total of 13,959 shares of Alzchem Group AG were acquired as part of the share [ … ]
Mon, 27.01.2025
Alzchem Group AG
Disclosure according to Article 5 of the EU Regulation 596/2014 and
Article 2 Section (1) of the Delegated EU Regulation 2016/1052
Trostberg, January 27th, 2025
6th Interim Report
In the period from January 20th up to and including January 24th, 2025, a total of 7,659 shares of Alzchem Group AG were acquired as part of the share [ … ]